Considering the effects of each immune cell and the clinicopathological features, including TNM stage and differentiation grades, on the prognosis of GC, CD68+ (hazard ratio (HR)  = 1.405; 95% confidence interval (CI)  = 1.059–1.866; P = 0.019), CD163+ (HR = 2.483; 95% CI = 1.824–3.380; P < 0.001), or CD66b+ cells (HR = 0.730; 95% CI = 0.543–0.982; P = 0.038) were independently associated with DFS. This evidence concerns the gene CD163 and gastric cancer.